TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05862272: A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Sponsor: Sumitomo Pharma Switzerland GmbH · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1000 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT05862272 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05862272 Rescue Dossier →